• 9 May 2018

    Dermatology: pharma’s latest focus

    Dermatology has recently become a point of interest for pharmaceutical innovation. Considering the total number of clinical trials in Phase II, III, and Pre-Registration stages, the already-crowded plaque psoriasis market...

  • 24 April 2018

    Tremfya approval: increasing options for psoriasis treatment

    Johnson & Johnson’s (J&J) Tremfya (guselkumab) has recently been granted approval for the treatment of adults suffering from moderate-to-severe plaque psoriasis in Australia, Brazil, and Japan. J&J has licensed Tremfya...